scholarly journals Invasive papillary ductal carcinoma of the breast: A case report

2020 ◽  
Vol 10 (1) ◽  
pp. 17
Author(s):  
Amani S Hadi ◽  
Gamal Abdul Hamid ◽  
Refaat Al-Areqee ◽  
Wafa Abdullah
Keyword(s):  
Papillary Carcinoma ◽  
Ductal Carcinoma ◽  
Radical Mastectomy ◽  
Residual Tumor ◽  
Excisional Biopsy ◽  
Breast Mass ◽  
Low Grade ◽  
Breast Cancers ◽  
History Of ◽  
Invasive Papillary Carcinoma

The general rate of intrusive papillary carcinoma (IPC) is uncommon, representing for less than 1-2 % of invasive breast cancers. They are most generally observed in postmenposal females and uncommon in males. Invasive papillary carcinomas are low grade tumors originating from large or dilated ducts. They are make out of all around outlined solid nodules of monotones neoplastic cell separated by network of fibrovascular cores, IPC is a remarkable sort of breast cancer and regarded of whether it is in-situ or invasive, it has brilliant prognosis. We presenting two cases of invasive papillary carcinoma in male and female; A case of 55years postmenoposal female who presented with history of left breast mass, which this mass notice after trauma same site for 1 year ago the mass gradually increase in size no tenderness, no signs of inflammation. Excisional biopsy was performed and specimen was histopathology diagnosed as invasive papillary carcinoma, left MRM was performed and histopathology diagnosis confirmed and without residual tumor seen in submitted slides and all submitted lymph nodes were free of tumor infiltration (0/14). IHC show ER and PR negative with HER-2 positive. The second case 70 years male presented with right breast mass and history of post-trauma since one year back with gradual increase in size, right radical mastectomy done and histopathology diagnosed as invasive papillary carcinoma, IHC was done ER and PR positive with HER2- negative.

scholarly journals EP.TH.3Male Breast Cancer: A Series of Three Extremely Rare Cases

2021 ◽  
Vol 108 (Supplement_7) ◽  
Author(s):  
Ahmed Latif ◽  
Amna Suliman ◽  
Anupama Nagarajakumar ◽  
Mihir Khan ◽  
Anna Metafa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Papillary Carcinoma ◽  
Ductal Carcinoma ◽  
Case Series ◽  
Mucinous Carcinoma ◽  
Wall Thickening ◽  
Low Grade ◽  
Breast Cancers ◽  
History Of ◽  
One Year

Abstract Aims Male breast cancer (MBC) is rare and accounts for 1% of all breast cancers. We present a case series of three very rare histological subtype MBC within one year in a UK hospital. Methods We retrospectively identified all MBCs from the local breast cancer database. Their presentations, radiology and histopathology were analysed. Results Three MBCs were identified from 2019 to 2020. A healthy 28-year-old presented with a right breast lump. Ultrasound (USS) revealed a partially cystic 15mm U3 lesion. Mammography (MMG) was suggestive of gynaecomastia (M2). Biopsy was inconclusive. Diagnostic excision revealed Papillary Ductal Carcinoma in Situ (DCIS) with involved margin. Mastectomy and Sentinel Node Biopsy (SNB) confirmed low-grade Papillary DCIS. A 48-year-old with background of hyperlipidaemia presented with a 2-year history of left axillary lump. PET CT demonstrated an FDG-avid lesion. USS showed a superficial U3 28mm lesion. MMG showed a 34mm density (M4). Biopsy identified Mucinous Carcinoma. Wide Local Excision and SNB confirmed grade 2 Mucinous Carcinoma. A 75-year-old with history of cardiac disease, COPD and Type 2 Diabetes, presented with a right retro-areolar lump. MMG identified a 47mm mass (M4). USS showed a 41mm cystic lesion with wall thickening (U4). Cytology was inconclusive. Biopsy identified intra-cystic papillary carcinoma. Mastectomy and SNB confirmed intra-cystic papillary carcinoma. All three histological subtypes are extremely rare and account for less than 4% of all MBCs. Conclusions MBC is rare but increasing in incidence. More research and awareness are needed to minimise delays in diagnosis and treatment even in young men.

scholarly journals Bilateral Neuroendocrine Carcinoma of Breast: A Case Report

2021 ◽  
Vol 59 (244) ◽  
pp. 1320-1322
Author(s):  
Sulochana Neupane ◽  
Sanam Dhakal ◽  
Shripad Walawalakar ◽  
Surya Bahadur Parajuli ◽  
Sulav Sapkota
Keyword(s):  
Ductal Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Radical Mastectomy ◽  
Left Breast ◽  
Breast Cancers ◽  
Breast Carcinomas ◽  
Breast Lump ◽  
History Of ◽  
Poorly Differentiated ◽  
Neuroendocrine Carcinomas

Primary neuroendocrine carcinomas of the breast are rare of all breast carcinomas. They may be welldifferentiated, poorly differentiated, or invasive breast cancers with neuroendocrine differentiation. They are staged and treated similarly to conventional breast cancer. Herein, we report a case of invasive ductal carcinoma with neuroendocrine differentiation of the breast in a 73 years female with a history of breast lump initially in the lower inner quadrant of left breast and a month later, similar lump at the same site in right breast. Patient underwent Modified Radical Mastectomy bilaterally followed by adjuvant chemotherapy based on Carboplatin and Etoposide regimen.

scholarly journals Lymphoepithelioma-Like Carcinoma of the Breast: A Case Report Unveiling Several Clinical and Histopathological Challenges

2018 ◽  
Vol 2018 ◽  
pp. 1-7
Author(s):  
Tarek Aridi ◽  
Mohamad Fawwaz ◽  
Ahmad Kassab ◽  
Marwan Bahmad ◽  
Faisal Houcheimi ◽  
...  
Keyword(s):  
Case Reports ◽  
Progesterone Receptors ◽  
Radical Mastectomy ◽  
Residual Tumor ◽  
Excisional Biopsy ◽  
Axillary Lymph ◽  
Tumor Type ◽  
Estrogen And Progesterone Receptors ◽  
Type Iv ◽  
Criteria For Diagnosis

Lymphoepithelioma-like carcinoma (LELC) of the breast is an extremely rare tumor type. Histologically, it mimics undifferentiated nasopharyngeal carcinoma by demonstrating nests of neoplastic epithelial cells in a background of lymphoplasmacytic infiltrates. This paper reports a 62-year-old female patient with a 3 × 1.5 cm BI-RADS type IV breast mass diagnosed on excisional biopsy as LELC. The tumor is negative for estrogen and progesterone receptors and did not overexpress HER2/neu. Routine tests for clearance before surgery were performed, and patient was managed by a modified radical mastectomy with axillary lymph node dissection showing no residual tumor. Surgical CAse REports (SCARE) guidelines were followed for reporting our case. The rarity of LELC of the breast warrants the establishment and implementation of well-defined guidelines and criteria for diagnosis and management.

Tubular Carcinoma of the Breast: Further Evidence to Support Its Excellent Prognosis

2010 ◽  
Vol 28 (1) ◽  
pp. 99-104 ◽  
Author(s):  
Emad A. Rakha ◽  
Andrew H.S. Lee ◽  
Andrew J. Evans ◽  
Sindhu Menon ◽  
Nancy Y. Assad ◽  
...  
Keyword(s):  
Ductal Carcinoma ◽  
Disease Free Survival ◽  
Distinct Type ◽  
Second Primary ◽  
Low Grade ◽  
Breast Cancers ◽  
Luminal A ◽  
Cancer Specific Survival ◽  
Tubular Carcinoma ◽  
Molecular Features

Purpose Although tubular carcinoma (TC) is known to have a favorable prognosis, it is still unknown whether this subtype represents a distinct type of breast carcinoma or whether it behaves like other low-grade luminal A–type breast carcinomas. Methods In this study, we performed a retrospective analysis of a large well-characterized series of breast cancers (2,608 carcinomas) to assess the clinicopathologic and molecular features and prognostic value of TC compared with grade 1 ductal carcinomas of the breast. Results When compared with grade 1 ductal carcinoma (n = 212), TC (n = 102) was more likely to be detected on mammographic screening, had smaller median size, and less frequently showed lymphovascular invasion. Compared with grade 1 ductal carcinoma, TC was associated with longer disease-free survival (χ2 = 13.25, P < .001) and breast cancer–specific survival (χ2 = 8.8, P = .003). In this study, none of the patients with TC developed distant metastasis or died from the disease without an intervening recurrence as invasive carcinoma of different histologic type. Conclusion We conclude that the biologic behavior of TC is excellent and is more favorable than that of grade 1 ductal carcinoma. Patients with TC may be at risk of developing second primary carcinomas in the contralateral breast, which may be of higher grade and poorer potential prognostic outcome. In addition, patients with TC seem to have a close to normal life expectancy, and as a consequence, adjuvant systemic therapy may not be justified in their routine management.

Prevalence of BRCA2 mutations and other clinical characteristics in women with triple-negative breast cancer.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 160-160
Author(s):  
Jennifer Chun ◽  
Freya Ruth Schnabel ◽  
Shira Schwartz ◽  
Jessica Billig ◽  
Karen Hiotis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
At Risk ◽  
Genetic Testing ◽  
Clinical Characteristics ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
Personal History ◽  
Breast Cancers ◽  
History Of ◽  
Brca2 Mutations

160 Background: Triple-negative breast cancers (TNBC) represent 10%–20% of invasive breast cancers. Current guidelines recommend genetic testing for women who are diagnosed with TNBC. Studies have shown that BRCA1 mutations are associated with TNBC, but there is little information on the relationship of BRCA2 mutations and TNBC. The purpose of this study was to look at the clinical characteristics of TNBC compared to non-TNBC in a cohort of women with newly diagnosed breast cancer. Methods: The Breast Cancer Database at our institution was queried for patients with invasive breast cancer. We included the following variables: age, race, BRCA1,2, tumor characteristics, and personal history of breast cancer (PHBC). Statistical analyses included Pearson’s Chi-Square and Fisher’s Exact Tests. Results: Out of a total of 1,332 women, 125 (9%) had TNBC. The median age for both TNBC and non-TNBC was 59 years. Majority of women had early stage breast cancer (92%) with ductal carcinoma (80%). There was a significantly higher proportion of Blacks and Asians with TNBC (p < 0.0001). Women with TNBC had higher Ki-67 (p < 0.0001). Within the TNBC group, there were 12 (29%) patients who tested positive for BRCA1,2 mutation and 23 (8%) who tested positive for BRCA 1,2 mutations in the non-TNBC group. Interestingly, BRCA1 was not associated with TNBC (p = 0.40) and BRCA2 was significantly associated with TNBC (p < 0.0001). We also found a higher proportion of TNBC in women who had a PHBC (p = 0.01). Conclusions: In our study, women with TNBC were similar in age to women who did not have TNBC. We found that the women with TNBC in our cohort had elevated rates of BRCA2 mutations. We also found that women with a personal history of breast cancer were at risk for developing TNBC. This may be related to the use of hormonal therapy that reduces the risk of ER/PR-positive tumors. Women of all ages are at risk for developing TNBC and older age at TNBC should not deter from genetic testing.

scholarly journals Neuroendocrine Differentiation in Breast Cancer: Clinicopathological Significance of Bcl-2 Positive Solid Papillary Carcinoma

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Yoichiro Okubo ◽  
Takuji Okubo ◽  
Yoshimi Okubo ◽  
Takao Ishiwatari
Keyword(s):  
Breast Cancer ◽  
Papillary Carcinoma ◽  
Neuroendocrine Tumors ◽  
Ductal Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Prognostic Indicator ◽  
Low Grade ◽  
Term Survival ◽  
Solid Papillary Carcinoma ◽  
Poor Prognostic Indicator

Solid papillary carcinoma (SPC) is considered a rare malignant breast tumor. Maluf and Koerner first reported this disease entity as a special type of ductal carcinoma in situ with several characteristic histopathological features, including low-grade cellular atypia, intracellular or extracellular mucin deposition, and solid papillary growth pattern, as well as neuroendocrine differentiation. The present paper describes a case of SPC with bcl-2 expression, which is known as a marker for malignancy of neuroendocrine tumors. Interestingly, despite bcl-2 expression being a poor prognostic indicator of neuroendocrine tumors, the patient with this tumor has achieved long-term survival (approximately 6 years) at the time of writing this report. Because previous investigators reported that bcl-2 expression might play a role in the inhibition of the development of breast cancer, we suggest that bcl-2 expression might reflect a good prognosis in patients with SPC, rather than being a poor prognostic indicator, as it is in several types of neuroendocrine tumor. However, to confirm this hypothesis, further investigation is required.

scholarly journals Invasive papillary carcinoma of the breast: a rare case report

2021 ◽  
Vol 52 (1) ◽  
Author(s):  
Pratibha Issar ◽  
M. Ravindranath ◽  
Manish Dewangan
Keyword(s):  
Papillary Carcinoma ◽  
Rare Case ◽  
Radical Mastectomy ◽  
Myoepithelial Cells ◽  
Left Breast ◽  
Good Prognosis ◽  
Menopausal Women ◽  
Malignant Breast ◽  
Post Menopausal ◽  
Invasive Papillary Carcinoma

Abstract Background Invasive Papillary Carcinomas (IPC) are rare and account for approximately 0.5% of all invasive breast carcinomas. Most of them are seen in post-menopausal women and have a good prognosis. These tumors lack the myoepithelial cell layer (MCL) within the papillae or at the periphery of the tumor with areas showing stromal invasion or invasion into lymphovascular spaces. Immunohistochemistry (IHC) for myoepithelial cells and basement membrane is essential for the diagnosis of invasive cancer. Case presentation We present a rare case of IPC in a 74-year-old woman who presented with complaints of gradually increasing painless retroaerolar mass in the left breast of two months duration. The mass was irregular, having an oblong as well an adjacent high density mass lesion on mammography. Ultrasound (US), and Magnetic Resonance Imaging (MRI) helped in the diagnosis of the possibility of a malignant breast lesion. Left-sided modified radical mastectomy was performed and the specimen was histopathologically diagnosed as Invasive Papillary carcinoma. Immunohistochemistry confirmed the diagnosis. Conclusions Invasive Papillary Carcinomas of the breast are rare cancers in post-menopausal women. We have highlighted the role of Mammography, US, and MRI in early diagnosis so that timely management is possible.

Comparison of serum HER-2/neu between trastuzumab-based regimen and anthyracycline-based regimen during neoadjuvant chemotherapy in advanced primary breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11582-e11582
Author(s):  
J. Lee ◽  
W. Min ◽  
S. Kim ◽  
B. Son
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Ductal Carcinoma ◽  
Pathologic Complete Response ◽  
Residual Tumor ◽  
Complete Response ◽  
Breast Cancers ◽  
Maximal Diameter ◽  
Her 2 ◽  
Positive Breast Cancer

e11582 Background: Serum Her-2/neu has been known as molecular surrogating marker of predicting treatment response in Her-2 positive breast cancer. We compare the change of serum Her-2/neu during neoadjuvant chemotherapy between trastuzumab(H) and anthyracyline(A) based treatment. Methods: All breast cancers were tested by immunohistochemical stain and FISH for Her-2/neu before treatment. Serum Her-2/neu was twice measured by Chemiluminescence immunoassay(ADVIA centaurTMsystem) before neoadjuvant chemotherapy and before operation. The cutoff value was 10.2 mg/ml according to previous study. Pathologic complete response (pCR) was considered as no residual tumor or remnant ductal carcinoma in situ, partial response (PR) was less than 50% decrease in maximal diameter in pathologic tumor size. Results: Serum Her-2/neu of trastuzumab group was more decreased than of anthyracyline group (H; 12.9 ± 14.5 ng/mL vs. A; 2.2 ± 1.2 ng/mL, p=0.024). In trastuzumab group, pCR was relatively correlated with decrease of serum Her-2/neu (PR: 0.8 ± 0.84 ng/ml vs. pCR: 21.1 ± 13.2 ng/ml, p=0.08). Conclusions: A decrease in serum Her-2/neu levels during treatment was associated with pathologic response in patients receiving neoadjuvant chemotherapy, particularly, trastuzumab-based regimen. Serum Her-2/neu levels may serve to monitoring neoadjuvant therapy in Her-2/neu positive breast cancer. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document